Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4231 to 4245 of 8926 results

  1. Reusing our content

    Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.

  2. Ensuring positive organisational change practices

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive workplaces for social

  3. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  4. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

  5. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

  6. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTG718)

    Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.

  7. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  8. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  9. Charging procedure

    Charging procedure for NICE technology appraisal and highly specialised technologies evaluations

  10. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  11. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  12. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  13. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

  14. Irreversible electroporation for treating pancreatic cancer (HTG437)

    Evidence-based recommendations on irreversible electroporation for treating pancreatic cancer. This involves inserting special needles into the tumour in the pancreas and using short electrical pulses to destroy the cancer cells.